181 related articles for article (PubMed ID: 34312131)
1. CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
Malik AA; Abbas H; Oo ZM; Lim Z
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34312131
[TBL] [Abstract][Full Text] [Related]
2. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib induced acute kidney injury: A case report.
Gulturk I; Yilmaz M; Ozmen A; Tacar SY; Erdal GS; Tural D
J Oncol Pharm Pract; 2021 Dec; 27(8):2023-2026. PubMed ID: 33847193
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
6. CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Meynard L; Grellety T
Breast J; 2020 Feb; 26(2):255-257. PubMed ID: 31495008
[TBL] [Abstract][Full Text] [Related]
7. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Weiss J; Afghahi A; Shagisultanova E; Diamond JR
Oncology (Williston Park); 2018 Oct; 32(10):513-5. PubMed ID: 30334242
[No Abstract] [Full Text] [Related]
8. MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Yardley DA
Future Oncol; 2019 Aug; 15(23):2673-2686. PubMed ID: 31305131
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
10. The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
Santti K; Beule A; Rönty M; Ihalainen H; Tarkkanen M; Blomqvist C
Acta Oncol; 2019 Jun; 58(6):897-900. PubMed ID: 30905251
[No Abstract] [Full Text] [Related]
11. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
Med Lett Drugs Ther; 2017 Oct; 59(1532):e178-e179. PubMed ID: 29039822
[No Abstract] [Full Text] [Related]
12. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
17. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
